Business Daily Media

Times Advertising

.

Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors

  • Written by ACN Newswire - Press Releases

Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors

NEW JERSEY, the U.S. and HANGZHOU, China, Sep 8, 2021 - (ACN Newswire) - Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple combination of AN2025 (buparlisib, oral pan-PI3K...

SME support in Federal Budget falls short of easing business pressures

“The Federal Budget delivered several measures aimed at supporting small businesses, including making the instant asset write-off permanent, exten...

Bunji dog treats to hit Ritchies shelves

Cooee Native Superfoods’ Bunji range of dog kibble and treats is rolling out across Ritchies Supermarkets now, with stock already on shelves in se...

Pre-Budget Expectations

“Australian corporates and SMBs are under pressure. Competition from global players is intensifying, margins are under strain, and technology adop...

“Time is running out to get Payday ready,” Brighter Super urges

Superannuation fund Brighter Super is encouraging business owners to prepare now for Payday Super, ahead of the new laws taking effect from 1 July...

PayNuts Unveils Expanded Integrated Solutions and Refreshed Brand to Support Australian SMEs

PayNuts, one of Australia’s fastest-growing payment service providers, has unveiled a refreshed brand identity and an expanded suite of integrated b...

BizCover Brings Australia’s First AI-Based Insurance Quotes to ChatGPT

Australian small business owners can now receive and compare business insurance quotes directly inside ChatGPT, in a move that signals a major shi...